Kaleido Biosciences Inc

NASDAQ:KLDO  
2.18
-0.07 (-3.11%)
Products, Strategic Combinations

Kaleido Biosciences Announces Expansion Of Collaboration With Janssen To Explore Potential Of Microbiome Metabolic Therapies (Mmt) To Prevent Childhood-Onset Of Atopic, Immune And Metabolic Cond

Published: 12/06/2021 14:14 GMT
Kaleido Biosciences Inc (KLDO) - Kaleido Biosciences Announces Expansion of Collaboration With Janssen to Explore Potential of Microbiome Metabolic Therapies (mmt™) to Prevent Childhood-onset of Atopic, Immune and Metabolic Conditions.
Kaleido Biosciences Inc - Existing Agreement With Janssen Has Been Extended.
Kaleido Biosciences Inc - Janssen Will Fund Additional Costs Associated With Expanded Scope of Collaboration.